Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

NCT03995017 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Esophagus Cancer, Adenocarcinoma
Stomach Cancer, Adenocarcinoma

Interventions

DRUG: Rucaparib
DRUG: Ramucirumab
DRUG: Nivolumab

Sponsor

University of Kansas Medical Center

Collaborators

[object Object]
[object Object]